Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Biden touts 'Cancer Moonshot' on JFK speech anniversary in Boston

Published 09/12/2022, 05:08 AM
Updated 09/13/2022, 10:16 AM
© Reuters. FILE PHOTO: U.S. President Joe Biden speaks to media before boarding Air Force One as he departs for Washington from New Castle, Delaware, U.S., September 11, 2022.      REUTERS/Joshua Roberts/File Photo
REGI
-
CTVA
-

By Nandita Bose and Trevor Hunnicutt

BOSTON (Reuters) -President Joe Biden signed orders on Monday to push more government dollars to the U.S. biotechnology industry, as he promoted his initiative to create new treatments and cut the death rate from cancer. Cancer "doesn’t care if you’re Republican or Democrat,” Biden said at the John F. Kennedy Library in Boston, on the 60th anniversary of JFK's 'Moonshot' speech that urged Americans to lead in the exploration of space.

Biden drew a parallel between the former president's goal of reaching the moon and his own goal of cutting cancer death rates in half in the next 25 years.

"Today I'm setting a long term goal for the Cancer Moonshot - to rally American ingenuity, we engage like we did to reach the moon, but actually cure cancers...once and for all," Biden said.

He said research could spark medical breakthroughs, including a vaccine to prevent cancer, or a blood test that could detect cancer in an annual physical.

The executive order allows the federal government to direct funding for the use of microbes and other biologically derived resources to make new foods, fertilizers and seeds, as well as making mining operations more efficient, administration officials said.

The order "directs the federal government to ensure biotechnologies invented in the United States of America are made in the United States of America," Biden said.

Biomanufacturing has been used to generate cancer treatments, including those derived from plants or using re-engineered immune cells.

The White House did not provide any specifics on how much money would be available, where it would come from or how it would be allocated. Further details are expected at a White House summit on the topic Wednesday.

The U.S. federal government is already a source of funds to biotechnology research and development (R&D) through the National Institute of Health, the U.S. Department of Agriculture and other agencies. Overall U.S. funding for R&D has dropped as a percentage of gross domestic product since a peak in the 1950s, a trend Biden has pledged to reverse.

Potential applications range from the biodiesel fuels made by Renewable Energy Group (NASDAQ:REGI) to the COVID-19 vaccines made by Pfizer-BioNTech or the genetically modified seeds made by Corteva (NYSE:CTVA) Inc.

© Reuters. FILE PHOTO: U.S. President Joe Biden speaks to media before boarding Air Force One as he departs for Washington from New Castle, Delaware, U.S., September 11, 2022.      REUTERS/Joshua Roberts/File Photo

Biden also named Dr. Renee Wegrzyn, a longtime science adviser and who most recently served at the biotech company Ginkgo Bioworks Holdings Inc, as the first director of the Advanced Research Projects Agency for Health, a U.S. government-run biomedical research group.

Biden's son Beau died of brain cancer in 2015 at age 46, something the president has said helps inform his passion for the project.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.